PRME Stock Price
Prime Medicine, Inc.
PRME stock price is $3.61 (-7.56% on the day), giving Prime Medicine, Inc. a market cap of $707.37M. Below are the price chart, the MarketXLS Rank, the company profile and the latest news.
PRME Stock Overview
- Price
- $3.60
- Previous close
- $3.90
- Open
- $3.83
- Market cap
- $707.37M
- P/E ratio
- -3.5
- 52-week range
- $2.67 - $6.94
- 1-year price target
- $7.02
- Exchange
- NSD
- MarketXLS Rank
- 62
About Prime Medicine, Inc.
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic therapies to address the spectrum of diseases by deploying gene editing technology in the United States. It offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and pegRNA which contains a search sequence, also known as a spacer, which provides a target genomic address for the Prime Editor. The company has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. Prime Medicine, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | PRME | $3.61 | -7.6% | 3.67M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |